МЕТОД АТОМНО-СИЛОВОЙ МИКРОСКОПИИ В ИССЛЕДОВАНИИ ТРОМБОЦИТОВ ПАЦИЕНТОВ С ТЕРМИНАЛЬНОЙ СТАДИЕЙ ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ

Atomic force microscopy was used to estimate the intravascular platelet activation and determine local elastic modulus, adhesion and stiffness of the platelets membrane in patients with end-stage of chronic heart failure with heart ventricle implantation before surgery and intrasurgical: before the heparin injection, after the heparin injection and after neutralization of heparin with protamine.Методом атомно-силовой микроскопии производилась оценка внутрисосудистой активации тромбоцитов и определялись локальный модуль упругости, адгезия, жесткость мембраны тромбоцитов у пациентов с терминальной стадией хронической сердечной недостаточности с использованием имплантируемого двухжелудочкового вспомогательного сердца на этапах до операции и интраоперационно: до введения гепарина, после введения гепарина, после нейтрализации гепарина протамином

Application of atomic force microscopy to evaluate the morphofunctional state of platelets in patients with end-stage heart failure

В работе методом АСМ определялись морфометрические характеристики тромбоцитов и тромбоцитарных агрегатов, а также локальные вязко-упругие характеристики мембраны кровяных пластинок (локальный модуль упругости, адгезия, жесткость) пациентов с терминальной стадией хронической сердечной недостаточности.In the study, the morphometric characteristics of platelets and platelet aggregates, as well as local viscoelastic characteristics of platelet membrane (local modulus of elasticity, adhesion, stiffness) of patients with end-stage heart failure were investigated by atomic force microscopy

Impact of COVID-19 on cardiovascular testing in the United States versus the rest of the world

Objectives: This study sought to quantify and compare the decline in volumes of cardiovascular procedures between the United States and non-US institutions during the early phase of the coronavirus disease-2019 (COVID-19) pandemic. Background: The COVID-19 pandemic has disrupted the care of many non-COVID-19 illnesses. Reductions in diagnostic cardiovascular testing around the world have led to concerns over the implications of reduced testing for cardiovascular disease (CVD) morbidity and mortality. Methods: Data were submitted to the INCAPS-COVID (International Atomic Energy Agency Non-Invasive Cardiology Protocols Study of COVID-19), a multinational registry comprising 909 institutions in 108 countries (including 155 facilities in 40 U.S. states), assessing the impact of the COVID-19 pandemic on volumes of diagnostic cardiovascular procedures. Data were obtained for April 2020 and compared with volumes of baseline procedures from March 2019. We compared laboratory characteristics, practices, and procedure volumes between U.S. and non-U.S. facilities and between U.S. geographic regions and identified factors associated with volume reduction in the United States. Results: Reductions in the volumes of procedures in the United States were similar to those in non-U.S. facilities (68% vs. 63%, respectively; p = 0.237), although U.S. facilities reported greater reductions in invasive coronary angiography (69% vs. 53%, respectively; p < 0.001). Significantly more U.S. facilities reported increased use of telehealth and patient screening measures than non-U.S. facilities, such as temperature checks, symptom screenings, and COVID-19 testing. Reductions in volumes of procedures differed between U.S. regions, with larger declines observed in the Northeast (76%) and Midwest (74%) than in the South (62%) and West (44%). Prevalence of COVID-19, staff redeployments, outpatient centers, and urban centers were associated with greater reductions in volume in U.S. facilities in a multivariable analysis. Conclusions: We observed marked reductions in U.S. cardiovascular testing in the early phase of the pandemic and significant variability between U.S. regions. The association between reductions of volumes and COVID-19 prevalence in the United States highlighted the need for proactive efforts to maintain access to cardiovascular testing in areas most affected by outbreaks of COVID-19 infection

Atomic force microscopy method in the study of platelets of patients with end-stage of chronic heart failure

Atomic force microscopy was used to estimate the intravascular platelet activation and determine local elastic modulus, adhesion and stiffness of the platelets membrane in patients with end-stage of chronic heart failure with heart ventricle implantation before surgery and intrasurgical: before the heparin injection, after the heparin injection and after neutralization of heparin with protamine

Atomic force microscopy method in the study of platelets of patients with end-stage of chronic heart failure

Методом атомно-силовой микроскопии производилась оценка внутрисосудистой активации тромбоцитов и определялись локальный модуль упругости, адгезия, жесткость мембраны тромбоцитов у пациентов с терминальной стадией хронической сердечной недостаточности с использованием имплантируемого двухжелудочкового вспомогательного сердца на этапах до операции и интраоперационно: до введения гепарина, после введения гепарина, после нейтрализации гепарина протамином. Atomic force microscopy was used to estimate the intravascular platelet activation and determine local elastic modulus, adhesion and stiffness of the platelets membrane in patients with end-stage of chronic heart failure with heart ventricle implantation before surgery and intrasurgical: before the heparin injection, after the heparin injection and after neutralization of heparin with protamine

Use of cardiac imaging in chronic coronary syndromes: the EURECA Imaging registry.

BACKGROUND: The prospective, multicentre EURECA registry assessed the use of imaging and adoption of the European Society of Cardiology (ESC) Guidelines (GL) in patients with chronic coronary syndromes (CCS). METHODS: Between May 2019 and March 2020, 5156 patients were recruited in 73 centres from 24 ESC member countries. The adoption of GL recommendations was evaluated according to clinical presentation and pre-test probability (PTP) of obstructive coronary artery disease (CAD). RESULTS: The mean age of the population was 64 ± 11 years, 60% of patients were males, 42% had PTP >15%, 27% had previous CAD, and ejection fraction was <50% in 5%. Exercise ECG was performed in 32% of patients, stress imaging as the first choice in 40%, and computed tomography coronary angiography (CTCA) in 22%. Invasive coronary angiography (ICA) was the first or downstream test in 17% and 11%, respectively. Obstructive CAD was documented in 24% of patients, inducible ischaemia in 19%, and 13% of patients underwent revascularization. In 44% of patients, the overall diagnostic process did not adopt the GL. In these patients, referral to stress imaging (21% vs. 58%; P < 0.001) or CTCA (17% vs. 30%; P < 0.001) was less frequent, while exercise ECG (43% vs. 22%; P < 0.001) and ICA (48% vs. 15%; P < 0.001) were more frequently performed. The adoption of GL was associated with fewer ICA, higher proportion of diagnosis of obstructive CAD (60% vs. 39%, P < 0.001) and revascularization (54% vs. 37%, P < 0.001), higher quality of life, fewer additional testing, and longer times to late revascularization. CONCLUSIONS: In patients with CCS, current clinical practice does not adopt GL recommendations on the use of diagnostic tests in a significant proportion of patients. When the diagnostic approach adopts GL recommendations, invasive procedures are less frequently used and the diagnostic yield and therapeutic utility are superior

Potentiation effect of the AMPK activator A-769662 on cardiac myocytes metabolism and survival

Abstract 286 van Poster session 2 Frontiers in CardioVascular Biology, London 30th March – 1st April 2012 Second Congress of the ESC Council on Basic Cardiovascular Science

Impact of COVID-19 on the imaging diagnosis of cardiac disease in Europe

Objectives We aimed to explore the impact of the COVID-19 pandemic on cardiac diagnostic testing and practice and to assess its impact in different regions in Europe. Methods The online survey organised by the International Atomic Energy Agency Division of Human Health collected information on changes in cardiac imaging procedural volumes between March 2019 and March/April 2020. Data were collected from 909 centres in 108 countries. Results Centres in Northern and Southern Europe were more likely to cancel all outpatient activities compared with Western and Eastern Europe. There was a greater reduction in total procedure volumes in Europe compared with the rest of the world in March 2020 (45% vs 41%, p=0.003), with a more marked reduction in Southern Europe (58%), but by April 2020 this was similar in Europe and the rest of the world (69% vs 63%, p=0.261). Regional variations were apparent between imaging modalities, but the largest reductions were in Southern Europe for nearly all modalities. In March 2020, location in Southern Europe was the only independent predictor of the reduction in procedure volume. However, in April 2020, lower gross domestic product and higher COVID-19 deaths were the only independent predictors. Conclusion The first wave of the COVID-19 pandemic had a significant impact on care of patients with cardiac disease, with substantial regional variations in Europe. This has potential long-term implications for patients and plans are required to enable the diagnosis of non-COVID- 19 conditions during the ongoing pandemic